Macro Biologics
Thursday, June 06, 2024
Company Presentation
Infectious Disease and Vaccines
Company Presentation Theater 1
Macro Biologics’ innovative technology platform creates synthetic biological polymers (macro biologics), inspired by nature. Our first class of synthetic macro biologics, Amicidins, combine a beneficial physical mode-of-action (barrier or surfactant) and broad microbicidal mode-of-action, including against antibiotic resistant bacteria. Their composition (amino acids), size, and self-assembly into multimers, yield a high level of performance and safety when applied locally to exposed, vulnerable tissues. Our first focus is prevention and treatment of life-threating healthcare-associated infections. Going forward, we anticipate Amicidins will go into a wide variety of products ranging from human therapeutics and devices to veterinary medicine / pet care to consumer health and cosmetics.
Company Website:
https://www.macrobiologics.com/
Lead Product in Development:
Amicidins are synthetic biologics made from amino acids and engineered for: 1) Beneficial physical properties (barrier or surfactant); 2) Broad microbicidal activity; and 3) Safety for people and the environment. Amicidins can be used to create new breakthrough products and improve existing ones for healthcare in hospitals & nursing homes, doctors offices, homes, and veterinary medicine.
Four investigational products are in advanced preclinical development - two with Amicidin-alpha and two with Amicidin-beta.
1. Amicidin-alpha Surgical is designed to prevent infection, as an adjunct to surgical procedures. It combines physical barrier to block and microbicidal activity to kill. IND is in preparation.
2. Amicidin-alpha PFC (Prolonged Field Care; supported by U.S. DoD) is for injured warfighters. It is a dry powder formulation designed to protect wounds for up to 72h.
3. Amicidin-beta Solution (supported by CARB-X) is designed to treat contaminated, colonized and infected tissues. It combines surfactant activity to cleanse with microbicidal activity to kill. IND is in preparation.
4. Amicidin-beta/EF (supported by UK GAMRIF & CARB-X) is designed for large surface area and cavity tissues (e.g., uterine cavity), including in low- and middle-income countries.
Additional investigational products are at prototyping stage in anticipation of corporate partnerships for R&D and commercialization.
Number Of Unlicensed Products (For Which You Are Seeking Partners):
More than a dozen. We anticipate Amicidins being used in new therapeutics and devices, products for veterinary medicine and pet care, as well as markets beyond healthcare like food & water and packaging.
Company HQ City
Carlsbad
Company HQ State
California
Company HQ Country
United States
CEO/Top Company Official
Michael P. Bevilacqua
Development Phase of Primary Product
Pre-Clinical
Speakers
)